SII resumes Covishield exports under COVAX

The Serum Institute of India (SII) on Friday officially announced that it has resumed exports of its COVID-19 vaccine Covishield under the international vaccine sharing programme COVAX.

The resumption of exports is linked to the SII surpassing its original target to produce one billion doses of Covishield by this year’s end, a statement issued by SII said, adding that it had reached this milestone ahead of time owing to the “rapid expansion of production capacity” at its Pune facility.

Earlier in the day, the first batches of Covishield left the SII manufacturing facility in Pune for distribution to low- and middle-income countries via the COVAX arrangement. SII’s supply of doses through COVAX is expected to increase substantially in the first quarter of next year, the statement added.

Adar Poonawalla, CEO of SII said in a statement: “I want to thank our workforce for their superhuman efforts in achieving this major milestone, with 1 billion doses of Covishield now produced by SII. We started to invest at-risk in COVID-19 vaccine production back in March 2020 and Serum Institute colleagues have worked tirelessly ever since to get these life-saving doses to people.”

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close